RT Journal Article
T1 The long non-coding RNA GHSROS reprograms prostate cancer cell lines toward a more aggressive phenotype.
A1 Thomas, Patrick B
A1 Jeffery, Penny
A1 Gahete, Manuel D
A1 Whiteside, Eliza
A1 Walpole, Carina
A1 Maugham, Michelle
A1 Jovanovic, Lidija
A1 Gunter, Jennifer
A1 Williams, Elizabeth
A1 Nelson, Colleen
A1 Herington, Adrian
A1 Luque, Raul M
A1 Veedu, Rakesh
A1 Chopin, Lisa K
A1 Seim, Inge
K1 Antisense transcript
K1 Gene expression
K1 Long non-coding RNA
K1 Prostate cancer
K1 Tumour growth
K1 lncRNA
AB It is now appreciated that long non-coding RNAs (lncRNAs) are important players in orchestrating cancer progression. In this study we characterized GHSROS, a human lncRNA gene on the opposite DNA strand (antisense) to the ghrelin receptor gene, in prostate cancer. The lncRNA was upregulated by prostate tumors from different clinical datasets. Transcriptome data revealed that GHSROS alters the expression of cancer-associated genes. Functional analyses in vitro showed that GHSROS mediates tumor growth, migration and survival, and resistance to the cytotoxic drug docetaxel. Increased cellular proliferation of GHSROS-overexpressing PC3, DU145, and LNCaP prostate cancer cell lines in vitro was recapitulated in a subcutaneous xenograft model. Conversely, in vitro antisense oligonucleotide inhibition of the lncRNA reciprocally regulated cell growth and migration, and gene expression. Notably, GHSROS modulates the expression of PPP2R2C, the loss of which may drive androgen receptor pathway-independent prostate tumor progression in a subset of prostate cancers. Collectively, our findings suggest that GHSROS can reprogram prostate cancer cells toward a more aggressive phenotype and that this lncRNA may represent a potential therapeutic target.
SN 2167-8359
YR 2021
FD 2021-02-01
LK https://hdl.handle.net/10668/25819
UL https://hdl.handle.net/10668/25819
LA en
DS RISalud
RD Apr 6, 2025